Asset
Relutrigine
Praxis Precision Medicines Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05818553 | phase2_3 | active_not_recruiting | 2023-08-02 | 2025-11-12 | Praxis Precision Medicines | A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) |
FDA applications (0)
This company has no applications containing this asset.